ZA200006817B - Combination therapy for treatment of Bipolar Disorders. - Google Patents
Combination therapy for treatment of Bipolar Disorders. Download PDFInfo
- Publication number
- ZA200006817B ZA200006817B ZA200006817A ZA200006817A ZA200006817B ZA 200006817 B ZA200006817 B ZA 200006817B ZA 200006817 A ZA200006817 A ZA 200006817A ZA 200006817 A ZA200006817 A ZA 200006817A ZA 200006817 B ZA200006817 B ZA 200006817B
- Authority
- ZA
- South Africa
- Prior art keywords
- olanzapine
- component
- composition
- group
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8712698P | 1998-05-29 | 1998-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006817B true ZA200006817B (en) | 2002-02-21 |
Family
ID=22203275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006817A ZA200006817B (en) | 1998-05-29 | 2000-11-21 | Combination therapy for treatment of Bipolar Disorders. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0966967A3 (pt) |
| JP (1) | JP2002516864A (pt) |
| KR (1) | KR20010043731A (pt) |
| CN (1) | CN1302207A (pt) |
| AU (1) | AU756468B2 (pt) |
| BR (1) | BR9911068A (pt) |
| CA (1) | CA2332408A1 (pt) |
| CZ (1) | CZ20004280A3 (pt) |
| EA (1) | EA003611B1 (pt) |
| HR (1) | HRP20000798A2 (pt) |
| HU (1) | HUP0102511A2 (pt) |
| IL (1) | IL139591A0 (pt) |
| NO (1) | NO20005884L (pt) |
| NZ (1) | NZ507981A (pt) |
| PL (1) | PL344304A1 (pt) |
| SK (1) | SK17492000A3 (pt) |
| TR (1) | TR200003525T2 (pt) |
| WO (1) | WO1999062522A1 (pt) |
| ZA (1) | ZA200006817B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| WO2000030648A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| FR2802101B1 (fr) * | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
| US6627653B2 (en) | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| NZ526801A (en) * | 2001-01-02 | 2005-07-29 | Upjohn Co | Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system |
| EP1404342A1 (en) * | 2001-04-26 | 2004-04-07 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| AU2003268026A1 (en) | 2002-07-30 | 2004-02-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| WO2004047727A2 (en) | 2002-11-01 | 2004-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for diagnosing and treating mood disorders |
| KR100858852B1 (ko) | 2002-12-27 | 2008-09-17 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| KR20060009938A (ko) * | 2003-05-16 | 2006-02-01 | 화이자 프로덕츠 인코포레이티드 | 양극성 장애 및 연관된 증상의 치료 |
| EP2601953A1 (en) * | 2003-05-23 | 2013-06-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| EP1713486A4 (en) * | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| JP2007513896A (ja) * | 2003-12-15 | 2007-05-31 | ハー・ルンドベック・アクチエゼルスカベット | セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用 |
| WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
| WO2005120523A1 (en) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Methods and compositions for treating mood disorder |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| DK2453024T3 (en) | 2004-06-21 | 2018-02-12 | Univ Leland Stanford Junior | Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder |
| AU2006315562C1 (en) | 2005-11-12 | 2013-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating depression using NCAM peptide mimetics |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| WO2007137167A2 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| US20080199866A1 (en) * | 2006-10-10 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Snp detection and other methods for characterizing and treating bipolar disorder and other ailments |
| GB0814466D0 (en) * | 2008-08-07 | 2008-09-10 | Rosemont Pharmaceuticals Ltd | Sertraline composition |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CN108938645A (zh) * | 2018-08-24 | 2018-12-07 | 山西医科大学第医院 | 一种抗精神病药物组合物 |
| CN108926569A (zh) * | 2018-08-24 | 2018-12-04 | 山西医科大学第医院 | 一种非典型抗精神病药物组合物 |
| CN109464436A (zh) * | 2019-01-10 | 2019-03-15 | 高智玉 | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 |
| CN110151718A (zh) * | 2019-06-13 | 2019-08-23 | 厦门医学院 | 一种奥氮平口腔崩解片及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8072691A (en) * | 1990-06-28 | 1992-01-23 | Beecham Group Plc | Pharmaceutical preparations |
| HUP9903679A3 (en) * | 1996-03-11 | 2001-10-29 | Lilly Co Eli | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder |
| NZ332039A (en) * | 1996-03-25 | 2000-06-23 | Lilly Co Eli | Method for treating pain using olanzapine and NSAIDs |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
-
1999
- 1999-05-21 HU HU0102511A patent/HUP0102511A2/hu unknown
- 1999-05-21 PL PL99344304A patent/PL344304A1/xx unknown
- 1999-05-21 BR BR9911068-7A patent/BR9911068A/pt not_active IP Right Cessation
- 1999-05-21 IL IL13959199A patent/IL139591A0/xx unknown
- 1999-05-21 EA EA200001244A patent/EA003611B1/ru not_active IP Right Cessation
- 1999-05-21 HR HR20000798A patent/HRP20000798A2/hr not_active Application Discontinuation
- 1999-05-21 KR KR1020007013060A patent/KR20010043731A/ko not_active Withdrawn
- 1999-05-21 CA CA002332408A patent/CA2332408A1/en not_active Abandoned
- 1999-05-21 WO PCT/US1999/011314 patent/WO1999062522A1/en not_active Ceased
- 1999-05-21 TR TR2000/03525T patent/TR200003525T2/xx unknown
- 1999-05-21 JP JP2000551778A patent/JP2002516864A/ja not_active Withdrawn
- 1999-05-21 CZ CZ20004280A patent/CZ20004280A3/cs unknown
- 1999-05-21 EP EP99303968A patent/EP0966967A3/en not_active Withdrawn
- 1999-05-21 NZ NZ507981A patent/NZ507981A/en unknown
- 1999-05-21 AU AU40088/99A patent/AU756468B2/en not_active Ceased
- 1999-05-21 CN CN99806479A patent/CN1302207A/zh active Pending
- 1999-05-21 SK SK1749-2000A patent/SK17492000A3/sk unknown
-
2000
- 2000-11-21 ZA ZA200006817A patent/ZA200006817B/en unknown
- 2000-11-21 NO NO20005884A patent/NO20005884L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1302207A (zh) | 2001-07-04 |
| IL139591A0 (en) | 2002-02-10 |
| BR9911068A (pt) | 2001-02-06 |
| SK17492000A3 (sk) | 2002-04-04 |
| EA003611B1 (ru) | 2003-06-26 |
| KR20010043731A (ko) | 2001-05-25 |
| AU756468B2 (en) | 2003-01-16 |
| JP2002516864A (ja) | 2002-06-11 |
| EP0966967A3 (en) | 2000-05-31 |
| PL344304A1 (en) | 2001-10-22 |
| HUP0102511A2 (hu) | 2001-11-28 |
| AU4008899A (en) | 1999-12-20 |
| CA2332408A1 (en) | 1999-12-09 |
| NO20005884D0 (no) | 2000-11-21 |
| CZ20004280A3 (cs) | 2001-09-12 |
| NO20005884L (no) | 2001-01-24 |
| EP0966967A2 (en) | 1999-12-29 |
| WO1999062522A1 (en) | 1999-12-09 |
| EA200001244A1 (ru) | 2001-06-25 |
| NZ507981A (en) | 2003-10-31 |
| TR200003525T2 (tr) | 2001-04-20 |
| HRP20000798A2 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200006817B (en) | Combination therapy for treatment of Bipolar Disorders. | |
| US20080107756A1 (en) | Lithium combinations, and uses related thereto | |
| US9808455B2 (en) | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline | |
| CA2332814C (en) | Combination therapy for treatment of refractory depression | |
| RS49828B (sr) | Farmaceutski sastavi | |
| US20030027817A1 (en) | Combination therapy for treatment of bipolar disorders | |
| JP2006528676A (ja) | 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ | |
| JP2008542378A (ja) | 精神病性障害を管理する方法および組成物 | |
| MX2008012094A (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion. | |
| US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
| CN101198322A (zh) | 用于治疗或预防抑郁症的新治疗组合 | |
| JP2016533374A (ja) | 吃音を治療するための融合ベンズアゼピン | |
| JP2010523640A5 (pt) | ||
| MXPA02005380A (es) | Tratamiento de combinacion para trastornos del sueno, incluyendo la apnea del sueno. | |
| RU2352336C2 (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| MXPA00011354A (en) | Combination therapy for treatment of bipolar disorders | |
| JP2007504180A (ja) | セロトニン再取り込み阻害剤およびアモキサピンの併用 | |
| JP2005060286A (ja) | 統合失調症の治療 | |
| HK1118712A (en) | Multimediator dopamine transport inhibitors, and uses related thereto |